The use of aromatase inhibitors might be justified by the fact that leiomyomata tend to overexpress aromatase.78 However, it must be considered that there might be a wide variation in drug metabolism and drug effects for patients taking aromatase inhibitors, therefore patients should have their own individualized treatment.78,87 As is the case with breast cancer patients, sex hormones levels may need to be regularly monitored.78 The gene discussed is CYP19A1; the disease is breast carcinoma.